This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Earnings Season Could Be Great for Genmab (GNMSF)
by Zacks Equity Research
Genmab (GNMSF) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Global Blood (GBT) reports narrower-than-expected loss in the first quarter of 2019.
Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.
Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates
by Zacks Equity Research
Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.
Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1
by Zacks Equity Research
Amicus (FOLD) reports wider-than-expected loss in the first quarter of 2019. Also, sales miss estimates.
AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates
by Zacks Equity Research
AMAG (AMAG) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.
What's in the Cards for AcelRx (ACRX) This Earnings Season?
by Zacks Equity Research
We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.
What's in Cards for Cumberland (CPIX) This Earnings Season?
by Zacks Equity Research
Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.
What's in the Cards for Corbus (CRBP) This Earnings Season?
by Zacks Equity Research
Corbus (CRBP) will provide updates on its lead candidate lenabasum, when it releases first-quarter 2019 results.
Seattle Genetics' Adcetris Progresses Well Amid Competition
by Zacks Equity Research
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
Seattle Genetics Closes Enrollment in Cervical Cancer Study
by Zacks Equity Research
Seattle Genetics (SGEN) and partner Genmab end enrollment in the phase II study on tisotumab vedotin for treating patients with advanced/metastatic cervical cancer.
Seattle Genetics, Astellas Report Positive Cancer Study Data
by Zacks Equity Research
Seattle Genetics (SGEN) and partner Astellas present positive top-line data from the first cohort of a phase II study on enfortumab vedotin for treating patients with advanced/metastatic urothelial cancer.
Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids
by Zacks Equity Research
Vertex (VRTX) gains an EU approval for Orkambi to treat 2-5-year-old children suffering cystic fibrosis (CF).
Genmab (GNMSF) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Genmab (GNMSF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2
by Zacks Equity Research
Dr. Reddy's (RDY) surpasses earnings and revenue estimates on strength across segments in the second quarter of fiscal 2019.
BioMarin (BMRN) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
BioMarin's (BMRN) Q3 scores on earnings and revenue beat with a surge in demand for its key products.
Seattle Genetics (SGEN) Q3 Loss In Line, Sales Top Mark
by Zacks Equity Research
Seattle Genetics' (SGEN) loss matches estimates but rides high on revenue beat in Q3.
Vertex (VRTX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex' (VRTX) Q3 gains on earnings and revenue beat with demand for its CF products rising high.
Emergent Completes Acquisition of Narcan Maker Adapt Pharma
by Zacks Equity Research
Emergent (EBS) wraps up the buyout of Adapt Pharma for $735 million. This strategic move will add the latter's popular Narcan nasal spray to its portfolio.
AcelRx's Dsuvia Gets FDA Committee Approval, Shares Rally
by Zacks Equity Research
AcelRx (ACRX) earns majority votes from an FDA advisory committee, which recommends approval of Dsuvia for treating moderate-to-severe acute pain in adult patients.
4 Biotech Stocks with Bright Prospects in 2017
by Zacks Equity Research
Even as the drug pricing issue continues to plague the biotech sector, investors should find it safe to bet on these top-ranked biotech stocks that also have superb Style Score as markets roll into 2017.
5 Top Performing Biotechnology Stocks of November
by Zacks Equity Research
November was a great month for pharma/biotech stocks after a rather difficult year when the industry struggled with media and political focus on high drug prices.
The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte